daridorexant

a new dual orexin receptor antagonist (DORA)

Also Known As:

((S)-(2-(5-chloro-4-methyl-1H-benzo(d)imidazol-2-yl)-2-methylpyrrolidin-1-yl) (5 methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone); ACT-541468; methanone, ((2S)-2-(6-chloro-7-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2H-1,2,3-traizol-2-yl)phenyl)-; nemorexant

Networked: 60 relevant articles (15 outcomes, 20 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - daridorexant: 60
  - Pyrrolidines: 115
    - daridorexant: 60

Experts

1.	Dingemanse, Jasper: 16 articles (01/2022 - 01/2019)
2.	Muehlan, Clemens: 10 articles (01/2022 - 01/2019)
3.	Fietze, Ingo: 5 articles (01/2022 - 01/2020)
4.	Ufer, Mike: 5 articles (01/2022 - 02/2019)
5.	Boof, Marie-Laure: 4 articles (01/2022 - 02/2019)
6.	Brooks, Sander: 4 articles (01/2022 - 01/2019)
7.	Berger, Benjamin: 4 articles (11/2021 - 12/2020)
8.	Zuiker, Rob: 4 articles (12/2020 - 01/2019)
9.	Pain, Scott: 3 articles (01/2022 - 01/2020)
10.	Zammit, Gary: 3 articles (01/2022 - 01/2020)

Related Diseases

1.	Sleep Initiation and Maintenance Disorders (Insomnia) 01/01/2023 - "Improvements in sleep and daytime functioning were maintained through to the end of the study and were most pronounced with daridorexant 50 mg. Daridorexant 50 mg, compared with placebo, increased self-reported total sleep time by a least-squares mean of 20.4 (95% confidence interval [CI] 4.2, 36.5), 15.8 (95% CI - 0.8, 32.5) and 17.8 (95% CI - 0.4, 35.9) minutes and decreased (i.e., improved) Insomnia Daytime Symptoms and Impacts Questionnaire total scores by a least-squares mean of - 9.3 (95% CI - 15.1, - 3.6), - 9.5 (95% CI - 15.4, - 3.5) and - 9.1 (95% CI - 15.6, - 2.7), at weeks 12, 24 and 36 of the extension study, respectively. " 01/01/2022 - "In this article, we review the most recent data on insomnia treatments and summarize the safety and efficacy of daridorexant in treating insomnia." 10/01/2021 - "Daridorexant is a new DORA that exhibited in phase 3 trials in insomnia not only a beneficial effect on sleep variables, measured objectively and assessed subjectively, but also an improvement in daytime functioning. " 10/01/2022 - "Daridorexant was approved in 2022 for the treatment of insomnia in adults following positive results in two trials that showed daridorexant significantly improved night-time sleep and daytime functioning over 3 months of treatment in adults with insomnia. " 01/01/2023 - "Both studies showed that, in patients with insomnia disorder, daridorexant improved night-time sleep and patients’ ability to function during the day, while avoiding major safety concerns. "
2.	Sleepiness 01/01/2022 - "Compared with the placebo group, participants in the daridorexant 25 mg group had significant improvement in self-reported total sleep time at month 1 (LSM difference 16·1 min [8·2 to 24·0], p<0·0001) and month 3 (19·1 [10·1 to 28·0], p<0·0001), but not in IDSIQ sleepiness domain scores (-0·8 [-1·6 to 0·1], p=0·073 at month 1; -1·3 [-2·2 to -0·3], p=0·012 at month 3). " 01/01/2022 - "Compared with the placebo group, participants in the daridorexant 25 mg group had significantly improved self-reported total sleep time at month 1 (LSM difference 12·6 min [5·0 to 20·3], p=0·0013) and month 3 (9·9 min [0·8 to 19·1], p=0·033), but not IDSIQ sleepiness domain scores (-0·8 [-1·5 to 0·01], p=0·055 at month 1; -1·0 [-2·0 to 0·01], p=0·053 at month 3). " 01/01/2022 - "Compared with placebo, participants in the daridorexant 50 mg group had significantly improved self-reported total sleep time at month 1 (LSM difference 22·1 min [14·4 to 29·7], p<0·0001) and month 3 (19·8 min [10·6 to 28·9], p<0·0001), and IDSIQ sleepiness domain scores at month 1 (-1·8 [-2·5 to -1·0], p<0·0001) and month 3 (-1·9 [-2·9 to -0·9], p=0·0002). " 01/01/2022 - "Compared with the placebo group, no significant differences were observed among participants in the daridorexant 10 mg group for WASO (LSM difference -2·7 min [-8·7 to 3·2], p=0·37 at month 1; -2·0 [-8·7 to 4·8], p=0·57 at month 3), LPS (-2·6 min [-8·4 to 3·2], p=0·38 at month 1; -3·2 min [-9·5 to 3·1], p=0·32 at month 3), self-reported total sleep time (13·4 min [5·5 to 21·2], p=0·0009 at month 1; 13·6 min [4·7 to 22·5], p=0·0028 at month 3), nor IDSIQ sleepiness domain scores (-0·4 [-1·3 to 0·4], p=0·30 at month 1; -0·7 [-1·7 to 0·2], p=0·14 at month 3). " 01/01/2023 - "Daridorexant did not induce next-morning sleepiness and no withdrawal-related symptoms or rebound were observed after treatment discontinuation. "
3.	Obstructive Sleep Apnea 01/01/2022 - "A study to investigate the effects of ACT-541468 on nighttime respiratory function in patients with mild to moderate obstructive sleep apnea. " 11/01/2021 - "A study to investigate the effects of ACT-541468 on nighttime respiratory function in patients with mild to moderate obstructive sleep apnea. " 01/01/2022 - "Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea." 11/01/2021 - "In this randomized, double-blind, placebo-controlled, two-period crossover study, the effect of the dual orexin receptor antagonist daridorexant was evaluated on nighttime respiratory function and sleep in 28 patients with mild and moderate obstructive sleep apnea (OSA). " 11/01/2021 - "Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea."
4.	Headache (Headaches) 07/01/2023 - "The drug was approved based on phase 3 trials involving study 1 and study 2. Study 1 noted daridorexant at doses of 25 and 50 mg demonstrated a statistically significant improvement in wake time after sleep onset, latency to persistent sleep, and self-reported total sleep time against placebo at months 1 and 3. Similarly in study 2, compared with placebo, the 25 mg dose demonstrated statistically significant improvement in wake time after sleep onset, latency to persistent sleep, and self-reported total sleep time at months 1 and 3. Treatment-emergent adverse events were similar for daridorexant and placebo, with nasopharyngitis and headache most frequently reported. " 01/01/2020 - "Treatment-emergent adverse events were similar for daridorexant and placebo; the most frequent were fatigue, nasopharyngitis, gait disturbance, and headache (≤7% in any group). " 12/01/2020 - "All treatments were generally well tolerated without serious adverse events (AEs). The most commonly reported treatment-emergent AEs following coadministration of daridorexant and ethanol included somnolence, headache, fatigue, sudden onset of sleep, and dizziness. "
5.	Nasopharyngitis 07/01/2023 - "The drug was approved based on phase 3 trials involving study 1 and study 2. Study 1 noted daridorexant at doses of 25 and 50 mg demonstrated a statistically significant improvement in wake time after sleep onset, latency to persistent sleep, and self-reported total sleep time against placebo at months 1 and 3. Similarly in study 2, compared with placebo, the 25 mg dose demonstrated statistically significant improvement in wake time after sleep onset, latency to persistent sleep, and self-reported total sleep time at months 1 and 3. Treatment-emergent adverse events were similar for daridorexant and placebo, with nasopharyngitis and headache most frequently reported. " 01/01/2020 - "Treatment-emergent adverse events were similar for daridorexant and placebo; the most frequent were fatigue, nasopharyngitis, gait disturbance, and headache (≤7% in any group). "

Related Drugs and Biologics

1.	Orexin Receptor Antagonists
2.	Benzodiazepines
3.	suvorexant
4.	lemborexant
5.	Trazodone (Trittico)
6.	Hypnotics and Sedatives (Sedatives)
7.	Zolpidem (Ambien)
8.	Member 1 Subfamily B ATP Binding Cassette Transporter
9.	Proteins (Proteins, Gene)
10.	Creatinine

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)